“IntraBio Inc. and IntraBio Limited (“IntraBio” or “Plaintiffs”) and Defendants Tesseract Medical Research, LLC, Tesseract Medical Research MidCo, Inc., and Tesseract Holding, LLC (“Tesseract” or “Defendants”), parties in the above-captioned action, have resolved this litigation for good cause and valuable consideration recognized by IntraBio and Tesseract. Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in the action, as follows: IT IS this _____ day of ___________, 2025: ORDERED, ADJUDGED AND DECREED as follows: 1. This District Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties. 2. As used in this Consent Judgment, (i) the term “Tesseract Product” shall mean a levacetylleucine (n-acetyl-L-leucine (“NALL”)) product sold, offered for sale or distributed by Tesseract; (ii) the term “Asserted Patents” shall mean United States Patent Nos. U.S. Patent Nos. 11,400,067 (“the ’067 Patent”), 11,471,434 (“the ’434 Patent”), 11,660,279 (“the ’279 Patent”), and 12,144,792 (“the ’792 Patent”); and (iii) the term “Affiliate” shall mean any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Tesseract; for purposes of this definition, “control” means (a) ownership, directly or through one or more intermediaries, of (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity. 3. Tesseract admits that the claims of the Asserted Patents are valid and enforceable. 4. Unless otherwise specifically authorized by IntraBio, Tesseract, including any of its Affiliates, successors and assigns, is enjoined from making, having made, marketing, selling, offering to sell, exporting, or distributing the Tesseract Product in violation of the state laws of California, Colorado, Florida, Tennessee, South Carolina, and Connecticut. 5. Compliance with this Consent Judgment may be enforced by IntraBio and its successors in interest, or assigns, as agreed by the parties. 6. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment. 7. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed without prejudice and without costs, disbursements or attorneys’ fees to any party.”